The Medicines Company's share price hit by dyslipidemia study setback

31 August 2016
2019_biotech_test_vial_discovery_big

The Medicines Company (Nasdaq: MDCO) saw its share price drop by nearly 4% to $38.65 on Wednesday morning after announcing a setback on its clinical dyslipidemia research.

Its programs were investigating MDCO-216 (containing APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor), and the USA-based biotech’s hopes to end its research early have been scuppered by inconclusive results.

The USA-based company announced that a planned, interim analysis of the first 40 randomized patients completing treatment in the MILANO-PILOT study of MDCO-216 has been reviewed by the study’s independent data monitoring committee.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology